As India strengthens its position as a global pharmaceutical manufacturing powerhouse, the Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, has extended support to M/s Bioneemtec India Private Limited, Chennai for the project titled “Manufacturing of Minoxidil, Tranexamic Acid, Dequalinium Chloride, their Intermediates and Drug Liposomes.” The project seeks to commercialize indigenous green chemistry technologies for the production of critical pharmaceutical ingredients and advanced drug delivery systems, contributing to import substitution, sustainable manufacturing, and healthcare security.

The project focuses on establishing advanced manufacturing capabilities for pharmaceutical intermediates, Active Pharmaceutical Ingredients (APIs), and novel drug delivery systems through a combination of batch and continuous-flow chemistry technologies. By adopting modern process technologies, the initiative aims to improve production efficiency, product quality, operational safety, and environmental sustainability while reducing dependence on imported pharmaceutical intermediates.

A key component of the project is the commercialization of an indigenous process for manufacturing Tranexamic Acid, an important therapeutic molecule used in the management of bleeding disorders. Developed using a cost-effective and environmentally responsible synthesis route, the technology is designed to deliver high-purity products while minimizing waste generation and process complexity. The project will also support the domestic production of Minoxidil and Dequalinium Chloride along with their key intermediates, strengthening local manufacturing capabilities in pharmaceutical value chains that presently depend substantially on imports.

Adding a strong innovation dimension, Bioneemtec has developed proprietary Drug Liposome APIs based on advanced nanotechnology platforms. These liposomal formulations are being developed for therapeutic applications including breast and skin cancer management and have demonstrated promising results with controlled nanoparticle characteristics. The company has also initiated intellectual property protection for the technology, creating a foundation for future development of advanced targeted drug delivery solutions.

Speaking on the occasion, Shri Rajesh Kumar Pathak, Secretary, TDB, stated, "The future of pharmaceutical manufacturing lies in sustainable, technology-driven production systems that combine quality, efficiency, and environmental responsibility. Indigenous development of advanced APIs, critical intermediates, and novel drug delivery platforms will be instrumental in strengthening India's position as a global pharmaceutical manufacturing hub. TDB is committed to supporting such innovative enterprises that are creating high-value technologies while contributing to import substitution and healthcare security."

Expressing gratitude for the support, the leadership of Bioneemtec India Private Limited stated that the project will enable the company to scale up commercialization of its green chemistry-based manufacturing technologies and advanced pharmaceutical products. The support will accelerate the development of indigenous capabilities in API manufacturing and next-generation therapeutic formulations while creating opportunities for domestic and international markets.

********

NKR/FT

(रिलीज़ आईडी: 2268897) आगंतुक पटल : 441